(Q47739523)

English

Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendation.

scientific article published on 19 May 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/22610512

Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendation. (English)

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/22610512

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Dongho Kim

1

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/22610512

Hyun Gyung Goh

2

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/22610512

Soo-Hyun Kim

3

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/22610512

Soo-Young Choi

4

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/22610512

Sa-Hee Park

5

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/22610512

Eun-Jung Jang

6

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/22610512

Dong-Wook Kim

7

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/22610512

publication date

19 May 2012

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/22610512

International Journal of Hematology

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/22610512

96

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/22610512

1

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/22610512

47-57

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/22610512

https://scigraph.springernature.com/pub.10.1007/s12185-012-1093-y

0 references

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1093-Y

21 January 2018

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1093-Y

21 January 2018

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1093-Y

21 January 2018

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1093-Y

21 January 2018

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1093-Y

21 January 2018

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1093-Y

21 January 2018

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1093-Y

21 January 2018

Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1093-Y

21 January 2018

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1093-Y

21 January 2018

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1093-Y

21 January 2018

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1093-Y

21 January 2018

Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1093-Y

21 January 2018

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1093-Y

21 January 2018

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1093-Y

21 January 2018

High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1093-Y

21 January 2018

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1093-Y

21 January 2018

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1093-Y

21 January 2018

Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1093-Y

21 January 2018

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1093-Y

21 January 2018

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1093-Y

21 January 2018

Structural modeling of V299L and E459K Bcr-Abl mutation, and sequential therapy of tyrosine kinase inhibitors for the compound mutations

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1093-Y

21 January 2018

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1093-Y

21 January 2018

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1093-Y

21 January 2018

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1093-Y

21 January 2018

Identifiers

10.1007/S12185-012-1093-Y

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/22610512

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/22610512

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47739523&oldid=1584530148"